title: [Interdisciplinary recommendations on targeted therapy in the treatment of renal cell carcinoma].
abstract: Recently, new data have been published on the treatment of metastasized renal cell cancer using targeted therapies. With the approval of the tyrosine kinase inhibitors Sunitinib and Sorafenib, two of these new therapies are now available in clinical practice. This has raised both new opportunities and new questions for the health care professionals involved. Here we report on a consensus conference addressing these questions with answers based on evidence from the recent literature.
authors.affiliation: Urologische Klinik, Charité Berlin, Germany. kurt.miller@charite.de
authors.forename: K
authors.initials: K
authors.lastname: Miller
authors.forename: L
authors.initials: L
authors.lastname: Bergmann
authors.forename: P
authors.initials: P
authors.lastname: Albers
authors.forename: E
authors.initials: E
authors.lastname: Jäger
authors.forename: G
authors.initials: G
authors.lastname: Jakse
authors.forename: J E
authors.initials: JE
authors.lastname: Geschwend
authors.forename: N
authors.initials: N
authors.lastname: Marschner
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001557:Benzenesulfonates / Q000008:administration & dosage / Q000627:therapeutic use*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy / Q000401:mortality / Q000473:pathology / Q000601:surgery / Q000628:therapy*; D018849:Controlled Clinical Trials as Topic; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use; D007167:Immunotherapy; D007211:Indoles / Q000008:administration & dosage / Q000627:therapeutic use*; D016898:Interferon-alpha / Q000627:therapeutic use; D007668:Kidney / Q000473:pathology; D007680:Kidney Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000473:pathology / Q000601:surgery / Q000628:therapy*; D015201:Meta-Analysis as Topic; D009362:Neoplasm Metastasis; D009392:Nephrectomy; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D011379:Prognosis; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D011725:Pyridines / Q000008:administration & dosage / Q000627:therapeutic use*; D011758:Pyrroles / Q000008:administration & dosage / Q000627:therapeutic use*; D000077157:Sorafenib; D000077210:Sunitinib; D013997:Time Factors
chemical_list: D000970:Antineoplastic Agents; D001557:Benzenesulfonates; D007155:Immunologic Factors; D007211:Indoles; D016898:Interferon-alpha; D010671:Phenylurea Compounds; D047428:Protein Kinase Inhibitors; D011725:Pyridines; D011758:Pyrroles; D009536:Niacinamide; D000077157:Sorafenib; D000077210:Sunitinib